Replies to post #18124 on MannKind Corp. (MNKD)

[B RY]

Early and often,lol. "Both MannKind and outsiders who believe Afrezza can still be a big seller agree that securing widespread coverage is a necessary first step to success. Of course, lowering prices will hurt margins on existing sales, but Pfeffer hopes to offset the damage by launching Afrezza in some of the many foreign markets that will rapidly approve drugs that already have FDA approval. MannKind reports that it is already in talks with potential partners from a number of countries that could approve Afrezza without any additional trials. These partners would use their knowledge of the local market not only to shepherd Afrezza onto pharmacy shelves, but also to market it to doctors and patients. Thanks to the potential for fast approval, such partnerships could begin boosting Afrezza sales just months after they start, said Pfeffer, who noted that any substantial increase in sales volume would mitigate the effect of domestic price cuts on margins byallowing MannKind factories to operate more efficiently, thus reducing unit costs."
 http://www.ajmc.com/journals/evidence-based-diabetes-management/2016/march-2016/MannKind-Path-to-Afrezza-Survival-Involves-Lower-Prices-to-Woo-Payers